Amarin Corp Plc (AMRN)

[dogn]

HC Wainwright Global Investment Conference comments

Notable points in my opinion:

KM separates US market into "exclusive" segment with stabilized volume and meaningful brand value vs. "nonexclusive" segment where plans are "just interested in having a generic" and "blended" offering to customers, where "we are not competing in any way." They have "from day one" been "ready to go for an authorized generic in the US, if need be" but are focusing for the moment on the brand... holding on to "45-50%" of lives in exclusive segment,

we're still maintaining a significant value out of that segment, so a lot of effort to conserve cash, yes, but we have to stay the course because there is still revenue to be made definitely in the brand and then, when it's time for the authorized generic, we will communicate that and we'll see how that one is going to go.

Appear quite ready for China launch, which "could be as big [an opportunity] as all of Europe", but cannot start manufacturing until get approval. BP partner negotiations underway.

Clearly focused much more on EU/ROW for combo pill "portfolio" with more than just statins as longer term means to manage lifecycle and extend exclusivity in X-US regions.

So for, you know, in Europe today, we have regulatory exclusivity until 2031. A fixed dose combination that is filed with new clinical data, and we don't mean outcome, you know your typical twelve week lipid type studies, will have additional, can potentially have additional exclusivity, maybe three years. So launching a fixed dose combination helps us extend the life cycle of the product, especially in Europe.

Not a certain strategy for regaining US market:

for the US it provides to us an opportunity maybe to come back to the market with a branded product that can potentially be protected because of its technology.

But we'll have to see where the price of Vascepa monotherapy will be at the time of launch because that's going to be very determining whether we launch or not in the US.

KM hints may be US market announcements in near future:

we hopefully will come out very soon with clear decisions on how it is all going to evolve from a domestic perspective on the US market

Are limiting GIA strategy to Europe, definitely now negotiating partners for ROW (20 additional markets outside EU). Recognize they cannot afford hubs in Asia and Latin America like their apparently very active EU hub in Zug.

Seem quite happy with price achieved in Sweden and optimistic for similar pricing elsewhere due to success of "value based pricing strategy," particularly in offering Vazkepa as a much less expensive product with superior outcomes compared to "injectable lipid lowering therapies which are very, very expensive." Confident Vazkepa can be shown to "save costs on MIs, on stroke, certainly hospitalization."

I think KM did a fine job selling Amarin as a solid long term investment with significant future growth potential. HODL.